{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-017070","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2026-05-14T20:23:47+00:00","discovered_at":"2026-05-14T20:25:00.306443+00:00","generated_at":"2026-05-14T20:25:23.450067+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GeoVax Q1 2026 net loss $5.3M; cash $1.3M; advances GEO-MVA Phase 3","bullets":["Net loss of $5.3M for Q1 2026 vs $5.4M in Q1 2025; no revenue vs $1.6M prior (BARDA contract terminated).","Cash $1.3M at March 31, 2026, down from $3.1M at Dec 31, 2025.","Phase 3 immunobridging study for GEO-MVA (mpox/smallpox) planned under EMA-aligned expedited pathway; enrollment ~500.","Completed cGMP manufacturing and fill/finish; CRO selected for trial initiation.","Exclusive license from Emory for Gedeptin in combination with immune checkpoint inhibitors."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-017070","json":"https://secwatch.observer/filing/0001437749-26-017070.json","markdown":"https://secwatch.observer/filing/0001437749-26-017070.md","text":"https://secwatch.observer/filing/0001437749-26-017070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774926017070/0001437749-26-017070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774926017070/govx20260513_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:25:23.450067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dcb97e83bfa3113ebc168bc25dc63e079668a7ee","claim":"GeoVax Labs, Inc. reported the quarter ended March 31, 2026 results: net income $5.3 million.","evidence_excerpt":"Net loss for the three months ended March 31, 2026, was $5.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774926017070/0001437749-26-017070-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"$5.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}